Flagship Harbor Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Flagship Harbor Advisors’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-509	Closed	-$9K	–	1620
2020 Q3	$9K	Sell	509 -354	-41%	-$6.45K	﹤0.01%	1370
2020 Q2	$15K	Buy	863 +265	+44%	+$4.76K	﹤0.01%	1237
2020 Q1	$9K	Buy	598 +150	+33%	+$2.72K	﹤0.01%	1277
2019 Q4	$9K	Buy	448 +6	+1%	+$115	﹤0.01%	1379
2019 Q3	$7K	Sell	442 -94	-18%	-$1.63K	﹤0.01%	1404
2019 Q2	$9K	Buy	536 +46	+9%	+$837	﹤0.01%	1341
2019 Q1	$10K	Buy	+490	New	+$9.86K	﹤0.01%	1304

Other funds holding TAK

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Flagship Harbor Advisors's TAK Position: Q4 2020 in Review

Flagship Harbor Advisors sold out of Takeda Pharmaceutical (TAK) in Q4 2020, closing a stake of 509 shares — an estimated $9K sold.

Flagship Harbor Advisors first reported a position in TAK in Q1 2019 and held it in 7 quarters. The position peaked at $15K in Q2 2020. 313 funds tracked by Wall St. Rank hold TAK as of Q4 2020.

Flagship Harbor Advisors reported no remaining Takeda Pharmaceutical position as of Q4 2020 after selling out during the quarter.
Flagship Harbor Advisors sold 509 Takeda Pharmaceutical shares in Q4 2020, an estimated $9K.
Flagship Harbor Advisors first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 7 quarters.
Flagship Harbor Advisors's Takeda Pharmaceutical position peaked at $15K in Q2 2020.
313 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2020.

Based on Flagship Harbor Advisors's 13F filing for Q4 2020, filed 8 Feb 2021.